Finally, when we treated NPC patient‐derived xenograft (PDX) tumor‐bearing mice anti‐INSL5 or GPCR142 neutralized antibodies, the tumor growth rate decreased, resulting in smaller tumor volume and lower tumor weight (Figs 6G and H and EV5D). Here, INSL5 is linked to nasopharyngeal carcinoma.